The availability of appropriate antimicrobial medicines gives doctors more options to provide the best treatment to their patients. Its availability is also important in the fight against antimicrobial resistance. Arikayce is an antimicrobial that was recently marketed in Belgium.
The FAMHP, in collaboration with other Belgian public services, has developed a Belgian One World, One Health national action plan on the fight against antimicrobial resistance. This plan is based on the three pillars of health: human, animal and environmental health, and suggests concrete actions to fight antimicrobial resistance in a universal and coordinated way. Actions to bring and maintain essential antimicrobials on the market are an integral part of it.
Arikayce liposomal 590 mg nebuliser dispersion for inhalation with amikacin (Insmed Netherlands bv) has been on the market since 8 August 2022. The method of administration by inhalation is new on the market. Arikayce liposomal is a new amikacin structure: this antibiotic is contained in tiny fat particles called liposomes, which allows the medicinal product to remain in the lungs for a longer period of time. Arikayce liposomal is indicated for the treatment of non-tuberculous mycobacterial (NTM) lung infections caused by Mycobacterium avium Complex (MAC) in adults with limited treatment options who do not have cystic fibrosis. Arikayce liposomal is the first and only treatment approved in the European Union for this indication.
You can check the availability of all (recently) marketed medicines in Belgium in PharmaStatus.
More information
Package leaflet and summary of product characteristics for Arikayce liposomal.